Back to Authors

Herrmann, Joerg

https://orcid.org/0000-0001-6675-4559

Mayo Clinic

Mayo Clinic

Citations 144

Differential Effect of Experimental Hypertension and Hypercholesterolemia on Adventitial Remodeling
Herrmann, Joerg , Samee, Saquib, Chade, Alejandro , Porcel, Martin Rodriguez, Lerman, Lilach O. , Lerman, Amir

Arteriosclerosis, Thrombosis, and Vascular Biology | January 27, 2005 | Volume: 25 | Issue: 2 | Pages: 447-453

10.1161/01.atv.0000152606.34120.97 Get It

Objective— Intima-media remodeling, as frequently assessed by changes in the external elastic lamina-to-lumen area (EELLA), is well-described in coronary artery disease in contrast to adventitial remodeling, especially in the early disease stage. Method and Results— Female domestic pigs were randomized to one of the following 12-week treatment groups: normal diet (N; n=6), high-cholesterol diet (HC; n=6), or renovascular hypertension (HT; n=4). Low-density lipoprotein (LDL) cholesterol serum concentration was higher in HC than in N and HT (395.5±106 versus 38.6±14 and 37.2±6.8 mg/dL; P <0.05 for both). Mean arterial pressure was higher in HT than in N and HC (141.3±21 versus 107.4±8.9 and 109.4±7.8 mm Hg; P <0.05 for both). EELLA ratio, as assessed by morphometry, was similar in N, HC, and HTN (1.03±0.32 versus 0.95±0.29 and 1.01±0.09; P <0.05 for both). Coronary vasa vasorum density, as assessed by 3-dimensional micro-computed tomography, was higher in HC than in N and HT (3.4±1.0 versus 1.9±0.3 and 2.0±1.2; P <0.05 for both). In contrast, immunostaining showed a higher collagen III content and the presence of adventitial myofibroblasts in HT compared with N and HC. Conclusions— The current study suggests that adventitial remodeling precedes intima and media remodeling of coronary arteries early after exposure to hypercholesterolemia and hypertension, with distinct qualitative differences between them.
Beneficial Effects of Antioxidant Vitamins on the Stenotic Kidney
Chade, Alejandro , Rodriguez‐Porcel, Martin , Herrmann, Joerg , Krier, James D., Zhu, Xiangyang , Lerman, Lilach O. , Lerman, Amir

Hypertension | August 19, 2003 | Volume: 42 | Issue: 4 | Pages: 605-612

10.1161/01.hyp.0000089880.32275.7c Get It

Renal artery stenosis (RAS) may lead to renal injury, partly mediated through increased oxidative stress. However, the potential effects of chronic oral antioxidant intervention on the stenotic kidney remain unknown. This study was designed to test the hypothesis that chronic antioxidant vitamin supplementation in RAS would preserve renal function and structure. Single-kidney hemodynamics and function were quantified in vivo in pigs using electron-beam CT after 12 weeks of unilateral RAS (n=7), a similar degree of RAS orally supplemented with vitamins C (1 g) and E (100 IU/kg) (RAS+Vitamins, n=7), or controls (normal, n=7). Renal tissue was studied ex vivo using Western blotting and immunohistochemistry. Mean arterial pressure was similarly elevated in both RAS groups, while ischemic renal volume and glomerular filtration rate were similarly reduced. Renal blood flow was decreased in RAS compared with normal (326.5±99.9 versus 553.4±48.7 mL/min, respectively, P =0.01), but preserved in RAS+Vitamins (485.2±104.1 mL/min, P =0.3 versus normal). The marked increase in the expression of the NADPH-oxidase subunits p47phox and p67phox, nitrotyrosine, endothelial and inducible nitric oxide synthase, and nuclear factor-κB observed in RAS ( P <0.05 versus normal) was normalized in RAS+Vitamins ( P >0.1). Furthermore, trichrome staining and the expression of transforming growth factor-β and tissue inhibitor of matrix-metalloproteinase-1 were also decreased in RAS+Vitamins. In conclusion, chronic blockade of the oxidative stress pathway in RAS using antioxidant vitamins improved renal hemodynamics and decreased oxidative stress, inflammation, and fibrosis in the ischemic kidney. These observations underscore the involvement of oxidative stress in renal injury in RAS and support a role for antioxidant vitamins in preserving the ischemic kidney.
Hypercholesterolemia and Hypertension Have Synergistic Deleterious Effects on Coronary Endothelial Function
Rodriguez‐Porcel, Martin , Lerman, Lilach O. , Herrmann, Joerg , Sawamura, Tatsuya , Napoli, Claudio , Lerman, Amir

Arteriosclerosis, Thrombosis, and Vascular Biology | May 9, 2003 | Volume: 23 | Issue: 5 | Pages: 885-891

10.1161/01.atv.0000069209.26507.bf Get It

Objective— Coronary endothelial dysfunction is associated with an increase in cardiac events. Hypercholesterolemia (HC) and hypertension (HT) are both associated with endothelial dysfunction, and their coexistence is associated with an increased incidence of cardiac events in epidemiological studies. However, pathogenic mechanisms are poorly understood. Here we studied the effects of coexisting HC and HT on coronary endothelial function. Methods and Results— Four groups of pigs were studied after 12 weeks of a normal diet (n=9), a 2% HC diet (n=9), HT (achieved by unilateral renal artery stenosis, n=8), or HC+HT (n=6). Coronary endothelial function was tested, in epicardial arteries and arterioles, by using organ chamber techniques. Oxidative stress was measured in coronary artery tissue. Vasodilatory response to bradykinin and calcium ionophore was significantly impaired in animals with HC+HT compared with each risk factor alone ( P <0.05 for both). In animals with coexistent HC and HT, the increase in oxidative stress was more pronounced compared with each risk factor alone ( P <0.05). Furthermore, chronic antioxidant supplementation significantly improved coronary artery vasoreactivity. Conclusions— These results suggest that HC and HT have a synergistic deleterious effect on coronary endothelial function, associated with increased oxidative stress. This interaction may contribute to the increased incidence of coronary heart disease and cardiac events seen when HC and HT coexist.
Preprocedural Statin Medication Reduces the Extent of Periprocedural Non–Q-Wave Myocardial Infarction
Herrmann, Joerg , Baumgart, Dietrich, Volbracht, Lothar, Schulz, Rainer , Birgelen, Clemens von , Haude, Michael , Heusch, Gerd , Erbel, Raimund, Lerman, Amir

Circulation | October 21, 2002 | Volume: 106 | Issue: 17 | Pages: 2180-2183

10.1161/01.cir.0000037520.89770.5e Get It

Background— Stenting-related myocardial injury has been recognized as a frequent and prognostically important event, the extent of which depends on microcirculatory impairment in association with platelet aggregation, inflammation, and increased oxidative stress. Recent studies underscored the non–lipid-lowering effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) with antithrombotic, antiinflammatory, and antioxidative aspects. Thus, we tested the hypothesis that preprocedural statin therapy is associated with a reduction in the extent of stenting-related myocardial injury. Methods and Results— We stratified 296 consecutive patients who were undergoing stenting of a de novo stenosis according to the preprocedural status of statin therapy (229 statin-treated and 67 control patients). Incidence of periprocedural myocardial injury was assessed by analysis of creatine kinase (CK; upper limit of normal [ULN] 70 IU/L for women, 80 IU/L for men) and cardiac troponin T (cTnT; bedside test; threshold 0.1 ng/mL) before and 6, 12, and 24 hours after the intervention. Relative to control patients, the incidence of CK elevation >3× ULN was more than 90% lower in statin-treated patients (0.4% versus 6.0%, P =0.01). Statin therapy was the only factor independently associated with a lower risk of CK elevation >3× ULN (OR: 0.08, 95% CI: 0.01 to 0.75; P =0.03). The overall incidences of CK and cardiac troponin T elevation were slightly lower in statin-treated than in control patients (14.4% versus 20.9%, P =0.3, and 17.9% versus 22.4%, P =0.5, respectively). Conclusions— Preprocedural statin therapy is associated with a reduction in the incidence of larger-sized, stenting-related myocardial infarctions. Prospective, randomized trials are warranted to further assess this cardioprotective effect of statins in coronary intervention.